Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072981 · ClinicalTrials.gov registry record · Phase 3
Immunotherapy Study for Surgically Resected Pancreatic Cancer
A Phase 3 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 722
- Enrollment target
NCT01072981 is a Phase 3 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 722 participants.
The verdict
NCT01072981, a Phase 3 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 722 participants
- Enrollment target
Study Summary
The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL HyperAcute-Pancreas Immunotherapy
- RADIATION 5FU Chemoradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2010-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072981
The ClinicalTrials.gov registry entry for NCT01072981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT01072981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072981 about?
NCT01072981 is a clinical study titled "Immunotherapy Study for Surgically Resected Pancreatic Cancer". The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
What is the current status of trial NCT01072981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 722 participants. The study started on 2010-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01072981?
The interventions under investigation include: Gemcitabine (DRUG), HyperAcute-Pancreas Immunotherapy (BIOLOGICAL), 5FU Chemoradiation (RADIATION).
Who is sponsoring clinical trial NCT01072981?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.